NR3C2 and systolic heart failure: The Randomized Aldactone Evaluation Study (RALES), Eplerenone Post–acute myocardial infarction Heart failure Efficacy and Survival Study (EPHESUS), and Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) showed that treatment with MR antagonists reduces the mortality and the number of hospitalizations in patients with mild to severe systolic heart failure [2]–[4].